These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19102718)

  • 1. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
    Parmeggiani F; Gemmati D; Costagliola C; Sebastiani A; Incorvaia C
    Pharmacogenomics; 2009 Jan; 10(1):81-95. PubMed ID: 19102718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration.
    Parmeggiani F; Costagliola C; Gemmati D; D'Angelo S; Perri P; Scapoli GL; Catozzi L; Federici F; Sebastiani A; Incorvaia C
    Pharmacogenet Genomics; 2007 Dec; 17(12):1039-46. PubMed ID: 18004208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.
    Parmeggiani F; Gemmati D; Costagliola C; Sebastiani A; Incorvaia C
    Recent Pat DNA Gene Seq; 2009; 3(2):114-22. PubMed ID: 19519581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia.
    Parmeggiani F; Gemmati D; Costagliola C; Semeraro F; D'Angelo S; Perri P; Sebastiani A; Incorvaia C
    Ophthalmology; 2010 Mar; 117(3):517-23. PubMed ID: 20044141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration.
    Parmeggiani F; Costagliola C; Semeraro F; Romano MR; Rinaldi M; Gallenga CE; Serino ML; Incorvaia C; D'Angelo S; De Nadai K; Dell'Omo R; Russo A; Gemmati D; Perri P
    Int J Mol Sci; 2015 Aug; 16(8):19796-811. PubMed ID: 26307969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic predictors of response to photodynamictherapy.
    Parmeggiani F; Gemmati D; Costagliola C; Semeraro F; Perri P; D'Angelo S; Romano MR; De Nadai K; Sebastiani A; Incorvaia C
    Mol Diagn Ther; 2011 Aug; 15(4):195-210. PubMed ID: 21913742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration.
    Parmeggiani F; Costagliola C; Gemmati D; D'Angelo S; Perri P; Campa C; Catozzi L; Federici F; Sebastiani A; Incorvaia C
    Invest Ophthalmol Vis Sci; 2008 Jul; 49(7):3100-6. PubMed ID: 18378576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration.
    Parmeggiani F; Gallenga CE; Costagliola C; Semeraro F; Romano MR; Dell'Omo R; Russo A; De Nadai K; Gemmati D; D'Angelo S; Bolletta E; Sorrentino FS
    Sci Rep; 2019 Feb; 9(1):2614. PubMed ID: 30796269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic aspects in therapeutic management of subfoveal choroidal neovascularisation: role of factor XIII-A 185 T-allele.
    Parmeggiani F; Costagliola C; Incorvaia C; Sebastiani A; Gemmati D
    Curr Drug Targets; 2011 Feb; 12(2):138-48. PubMed ID: 20887247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties.
    Cruess AF; Zlateva G; Pleil AM; Wirostko B
    Acta Ophthalmol; 2009 Mar; 87(2):118-32. PubMed ID: 18577193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration.
    Incorvaia C; Campa C; Parmeggiani F; Menzione M; D'Angelo S; Della Corte M; Rinaldi M; Romano M; Dell'omo R; Costagliola C
    Retina; 2008 Feb; 28(2):289-97. PubMed ID: 18301052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy with verteporfin following transpupillary thermotherapy for CNV evolving from an initially occult to a predominantly classic form, in patients with AMD.
    Hamon F; Goeminne P
    Semin Ophthalmol; 2001 Dec; 16(4):223-32. PubMed ID: 15513445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy for age-related macular degeneration.
    Jin C; Ge J; Zhou S; Chen H; Zhong X; Jiang R; Chen L; Chen L
    Yan Ke Xue Bao; 2004 Sep; 20(3):158-62. PubMed ID: 15499723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration.
    Feng X; Xiao J; Longville B; Tan AX; Wu XN; Cooper MN; McAllister IL; Isaacs T; Palmer LJ; Constable IJ
    Ophthalmology; 2009 Oct; 116(10):1908-12.e1. PubMed ID: 19692124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
    Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
    Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists--comments on the current therapy for neovascular AMD].
    Pauleikhoff D; Bornfeld N; Gabel VP; Holz F; Roider H; ; ;
    Klin Monbl Augenheilkd; 2005 May; 222(5):381-8. PubMed ID: 15912454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Photodynamic therapy in age-related macular degeneration--results of one year observation].
    Wykrota H; Gierek-Łapińska A
    Klin Oczna; 2002; 104(3-4):239-43. PubMed ID: 12608309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: from clinical trials to clinical practice.
    Sickenberg M
    Semin Ophthalmol; 2001 Dec; 16(4):207-12. PubMed ID: 15513442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.